Cerus Corporation reports Q3 product revenue of $52.7 million and narrows net loss to $0.02 million
Reuters
Nov 07
<a href="https://laohu8.com/S/CERS">Cerus Corporation</a> reports Q3 product revenue of $52.7 million and narrows net loss to $0.02 million
Cerus Corporation reported total revenue of $60.2 million for the third quarter of 2025, a 19% increase compared to $50.7 million in the same period of 2024. Product revenue rose 15% year-over-year to $52.7 million, driven by growth in IFC and global platelet sales. Government contract revenue reached $7.5 million, up 63% from the prior year, primarily due to funding for research and development activities related to the INTERCEPT RBC program and next-generation pathogen reduction technology. The company's GAAP net loss narrowed to $0.02 million for the third quarter, compared to a net loss of $2.9 million in the same period last year. Non-GAAP adjusted EBITDA was positive at $5.0 million, up from $4.4 million a year ago. As of September 30, 2025, cash, cash equivalents, and short-term investments totaled $78.5 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerus Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106347740) on November 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.